Astragalus membranaceus extract,
does it really help with Immune enhancement and infection prevention?
research showsAstragalus immune literature is dominated by cell and animal work, injections, multi-herb formulas, and surrogates such as immune cells and cytokines. A Cochrane review of recurrent acute respiratory infection prevention in children found no oral Astragalus RCT meeting its placebo-controlled criteria. A standalone standardized-extract human trial exists, but it assessed immune markers in only 18 athletes and did not test infection prevention.
ads claimTraditional tonic use, cell activation, cytokine changes, or results from multi-herb formulas should not be repurposed as clinical infection-prevention efficacy of standalone Astragalus.
Useful facts when choosing a product
- Astragalus is sold in Korea as a food or herbal material and in mixed wellness products, with widely varying extraction and formulation.
- The 18-person trial used 1 g/day of extract standardized to 0.5% 3-hydroxy-7-methoxy isoflavonoids.
- Results from formulas, decoctions, or injections do not automatically apply to standalone oral Astragalus extract.
What the research actually shows
The Cochrane review of recurrent pediatric respiratory infection prevention screened 6,080 records and assessed 120 full texts but found zero eligible placebo-controlled RCTs of oral standalone Astragalus. A separate randomized double-blind placebo-controlled trial in 18 rowers used standardized Astragalus for six weeks and measured NK cells, Treg cells, and cytokines, but not infection incidence.
Why this is classified as C (42)
Zero eligible Cochrane trials means the infection-prevention subclaim is unknown, not disproven. The 18-person human RCT supplies grade-C surrogate evidence for immune markers. Distinguishing those axes yields an overall C with 42 points.
Counterpoint. A sufficiently powered independent placebo-controlled trial with infection incidence as the primary endpoint is needed.
Rejudgment record. Reassessment (cross-check reflected) — Reclassified zero eligible Cochrane trials as absence of testing rather than inefficacy and applied a C ceiling to the 18-person human immune-surrogate RCT
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improvement in immune markers (NK cells and cytokines) | C | Surrogate outcomes only in a trial of 18 participants |
| Infection prevention | ? | No eligible human placebo-controlled RCT (zero eligible Cochrane trials) |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Su et al. (2016), Cochrane Database of Systematic Reviews | Systematic review of randomized oral Astragalus trials for recurrent acute respiratory infection prevention in children | 0 | Cochrane review with no included trials | Prevention of recurrent acute respiratory infections | No RCT met the placebo-controlled eligibility criteria, so efficacy could not be assessed | High |
| Latour et al. (2021), Journal of the International Society of Sports Nutrition | Randomized double-blind placebo-controlled trial, six weeks | 18 | Publicly supported by the Polish Ministry of Sport and Tourism; no conflict reported | Immune cells, cytokines, and cortisol before and after exercise | Some immune-marker changes occurred, but findings were mixed and infection incidence was not measured | Low |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-16).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-16 · Corrections: none
Cite this verdict
[Chamgap] Does Astragalus extract enhance immunity and prevent infections? — Evidence Grade C·42. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/astragalus-membranaceus/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.